Shareholders Claim Biogen Skipped $50M Drug Payment
Former shareholders of a U.K.-based drug company accused Biogen of failing to make a $50 million payment under a deal to acquire the company and its nerve pain medication, on the...To view the full article, register now.
Already a subscriber? Click here to view full article